Title:
UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER
Document Type and Number:
WIPO Patent Application WO/2020/079184
Kind Code:
A3
Abstract:
The present invention relates to a compound or a pharmaceutically acceptable salt thereof of formulae (I) and (II), and a pharmaceutical composition comprising such compound for use for treating a cancer, particularly a cancer overexpressing CXCR1 and CXCR2 receptors, such as medulloblastoma, head and neck and kidney cancer. The invention further relates to such compounds for use for treating macular degeneration.
More Like This:
| JP2001527513 | INDUSTRIAL APPLICABILITY: Spiro ring integrin inhibitor |
| JP2016106149 | ANTIVIRAL COMPOUND |
Inventors:
BENHIDA RACHID (FR)
PAGES GILLES (MC)
DUFIES MAEVA (FR)
DEMANGE LUC (FR)
RONCO CYRIL (FR)
GRYTSAI OLEKSANDR (FR)
PAGES GILLES (MC)
DUFIES MAEVA (FR)
DEMANGE LUC (FR)
RONCO CYRIL (FR)
GRYTSAI OLEKSANDR (FR)
Application Number:
PCT/EP2019/078274
Publication Date:
May 22, 2020
Filing Date:
October 17, 2019
Export Citation:
Assignee:
CENTRE NAT RECH SCIENT (FR)
INST NAT SANTE RECH MED (FR)
UNIV PARIS DESCARTES (FR)
UNIV NICE SOPHIA ANTIPOLIS (FR)
INST NAT SANTE RECH MED (FR)
UNIV PARIS DESCARTES (FR)
UNIV NICE SOPHIA ANTIPOLIS (FR)
International Classes:
A61K31/4184; A61K31/428; A61P27/00; A61P35/00
Domestic Patent References:
| WO2001057008A1 | 2001-08-09 |
Foreign References:
| EP2949651A1 | 2015-12-02 |
Other References:
WESAM E. MEHANNA ET AL: "Synthesis, ADMET Properties, and Biological Evaluation of Benzothiazole Compounds Targeting Chemokine Receptor2 (CXCR2)", CHEMMEDCHEM, vol. 12, no. 13, 14 June 2017 (2017-06-14), DE, pages 1045 - 1054, XP055579147, ISSN: 1860-7179, DOI: 10.1002/cmdc.201700229
Attorney, Agent or Firm:
CABINET BECKER ET ASSOCIES (FR)
Download PDF:
Previous Patent: APPARATUS AND METHOD FOR MANUFACTURING BAKED WAFFLE CONE SHEETS
Next Patent: DRY PHARMACEUTICAL COMPOSITION FOR INHALATION
Next Patent: DRY PHARMACEUTICAL COMPOSITION FOR INHALATION